Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients

Marianna Buttarelli, Alessandra Ciucci, Fernando Palluzzi, Giuseppina Raspaglio, Claudia Marchetti, Elisabetta Perrone, Angelo Minucci, Luciano Giacò, Anna Fagotti, Giovanni Scambia, Daniela Gallo

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Background: High-grade serous ovarian cancer (HGSOC) has poor survival rates due to a combination of diagnosis at advanced stage and disease recurrence as a result of chemotherapy resistance. In BRCA1 (Breast Cancer gene 1) - or BRCA2-wild type (BRCAwt) HGSOC patients, resistance and progressive disease occur earlier and more often than in mutated BRCA. Identification of biomarkers helpful in predicting response to first-line chemotherapy is a challenge to improve BRCAwt HGSOC management. Methods: To identify a gene signature that can predict response to first-line chemotherapy, pre-treatment tumor biopsies from a restricted cohort of BRCAwt HGSOC patients were profiled by RNA sequencing (RNA-Seq) technology. Patients were sub-grouped according to platinum-free interval (PFI), into sensitive (PFI > 12 months) and resistant (PFI < 6 months). The gene panel identified by RNA-seq analysis was then tested by high-throughput quantitative real-time PCR (HT RT-qPCR) in a validation cohort, and statistical/bioinformatic methods were used to identify eligible markers and to explore the relevant pathway/gene network enrichments of the identified gene set. Finally, a panel of primary HGSOC cell lines was exploited to uncover cell-autonomous mechanisms of resistance. Results: RNA-seq identified a 42-gene panel discriminating sensitive and resistant BRCAwt HGSOC patients and pathway analysis pointed to the immune system as a possible driver of chemotherapy response. From the extended cohort analysis of the 42 DEGs (differentially expressed genes), a statistical approach combined with the random forest classifier model generated a ten-gene signature predictive of response to first-line chemotherapy. The ten-gene signature included: CKB (Creatine kinase B), CTNNBL1 (Catenin, beta like 1), GNG11 (G protein subunit gamma 11), IGFBP7 (Insulin-like growth factor-binding protein 7), PLCG2 (Phospholipase C, gamma 2), RNF24 (Ring finger protein 24), SLC15A3 (Solute carrier family 15 member 3), TSPAN31 (Tetraspanin 31), TTI1 (TELO2 interacting protein 1) and UQCC1 (Ubiquinol-cytochrome c reductase complex assembly factor). Cytotoxicity assays, combined with gene-expression analysis in primary HGSOC cell lines, allowed to define CTNNBL1, RNF24, and TTI1 as cell-autonomous contributors to tumor resistance. Conclusions: Using machine-learning techniques we have identified a gene signature that could predict response to first-line chemotherapy in BRCAwt HGSOC patients, providing a useful tool towards personalized treatment modalities.
Lingua originaleEnglish
pagine (da-a)1-17
Numero di pagine17
RivistaJOURNAL OF EXPERIMENTAL &amp; CLINICAL CANCER RESEARCH
Volume41
DOI
Stato di pubblicazionePubblicato - 2022

Keywords

  • BRCA1 Protein
  • Bioinformatics
  • Biomarkers
  • Drug-resistance
  • Female
  • Gene Expression Profiling
  • HGSOC
  • Humans
  • Neoplasm Grading
  • Ovarian Neoplasms
  • Patient stratification
  • Primary ovarian cancer cells
  • Random forest classifier model
  • Retrospective Studies
  • Survival Analysis
  • Transcriptomic

Fingerprint

Entra nei temi di ricerca di 'Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients'. Insieme formano una fingerprint unica.

Cita questo